We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galera Therapeutics Inc | NASDAQ:GRTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0001 | -0.05% | 0.1897 | 0.1851 | 0.1897 | 2,118 | 10:21:32 |
Presentation Details: | |
Event: | Jefferies London Healthcare Conference |
Date: | November 18, 2021 |
Time: | On-demand beginning at 8:00 a.m. GMT (3:00 a.m. ET) |
Event: | Piper Sandler Annual Healthcare Conference |
Date: | November 22, 2021 |
Time: | On-demand beginning at 10 a.m. ET |
Webcasts from the two presentations will be accessible from the Investors page of Galera’s website, investors.galeratx.com. Following the event, archived webcasts will be available on the Galera website for 30 days.
About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including SOM in patients with head and neck cancer and esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara LockshinSolebury Trout646-378-2960zlockshin@soleburytrout.com
1 Year Galera Therapeutics Chart |
1 Month Galera Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions